• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.08% Nasdaq Up0.40%

    More On 009420.KS



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    HanAll Biopharma Co., Ltd. (009420.KS)

    11,550.00 Up 850.00(7.94%) Jul 31, 2:00AM EDT
    Add to Portfolio
    ProfileGet Profile for:
    HanAll Biopharma Co., Ltd.
    I-Space Building
    6th Floor
    Seoul, 138-922
    South Korea - Map
    Phone: 82 2 2204 1753
    Fax: 82 2 414 1951
    Website: http://www.hanallbiopharma.com

    Index Membership:N/A
    Full Time Employees:N/A

    Business Summary 

    HanAll BioPharma Co., Ltd., a biopharmaceutical company, researches and develops biopharmaceutical products worldwide. It develops H176 and HL177, a series of anti-cancer agents for cancer metabolism; and HL156FIB, an EMT inhibitor for fibrotic diseases, such as IPF, peritoneal fibrosis, hypertrophic scar, etc. The company also develops products for infectious diseases, such as HL143, a single amino acid variant of native IFN-alpha-2a; and Hanferon, a protease resistant for genotype 1 hepatitis C patients. In addition, it provides HL036, a TNF-alpha receptor fragment for the treatment of inflammatory diseases caused by TNF-alpha, such as uveitis, dry eyes, and AMD. Further, the company offers HL161, an anti-FcRn mAb for the treatment of autoimmune diseases caused by IgG auto antibodies and immune complex mediated glomerular diseases; and HL009, an adenosylcobalamin liposomal gel in the area of immunology diseases. Additionally, it provides Vitatropin, an oral human growth hormone, as well as HL-178, a negative regulator of TXNIP in the area of endocrinology diseases; and HL040, a combination of atorvastatin and losartan for the treatment of cardiovascular disease, such as hypertension and hyperlipidemia. The company also exports its products. HanAll BioPharma Co., Ltd. was founded in 1973 and is headquartered in Seoul, South Korea.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on HanAll Biopharma Co., Ltd.

    Key Executives 
    Han-Soo Lee , 51
    Exec. Director of Fin. and Director
    Mr. Seung-Kook Park Ph.D., M.B.A., 52
    Head of Research, Exec. VP and Director
    Soon-Im Lee , 45
    Director of Devel.
    Mr. Seong-Jin Kim , 54
    Exec. Director of HR and Director
    Chang-Hee Min Ph.D., 54
    Head of Central R&D
    Amounts are as of Dec 31, 2011 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in KRW.